Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017-Reference-Cited by-同舟云学术

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017

Published:2020-10-22 Issue:5 Volume:17 Page:1536-1545
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Fergie Jaime¹,Goldstein Mitchell²,Krilov Leonard R.³,Wade Sally W.⁴^ORCID,Kong Amanda M.⁵,Brannman Lance⁶

Affiliation:

1. Infectious Diseases Service, Driscoll Children’s Hospital, Corpus Christi, TX, USA

2. Department of Pediatrics, Loma Linda University Children’s Hospital, Loma Linda, CA, USA

3. Department of Pediatrics, NYU Winthrop Hospital and the NYU Long Island School of Medicine, Mineola, NY, USA

4. Wade Outcomes Research and Consulting, Salt Lake City, UT, USA

5. Department of Life Sciences, IBM Watson Health, Cambridge, MA, USA

6. US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA

Funder

AstraZeneca

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1822134

Reference29 articles.

1. Respiratory Syncytial Virus and Parainfluenza Virus

2. The Burden of Respiratory Syncytial Virus Infection in Young Children

3. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

4. Respiratory Syncytial Virus Seasonality — United States, 2014–2017

5. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration;Human Vaccines & Immunotherapeutics;2023-08

2. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection;Pediatrics;2023-06-26

3. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood;Jornal de Pediatria;2023-03

4. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020;Human Vaccines & Immunotherapeutics;2022-11-22

5. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab;American Journal of Perinatology;2022-10-28